F2 Ventures

4M Analytics is a geo-data company specializing in subsurface infrastructure mapping. It has developed a sophisticated mapping engine that supports utility and infrastructure construction projects during the pre-planning and planning phases. This technology utilizes artificial intelligence and analytics to analyze satellite and aerial imagery, allowing for the creation of detailed and accurate subsurface infrastructure maps without the need for prior as-built data. The platform provides clients with cloud-based location intelligence, enabling them to identify known and unknown utilities within a specified area. By combining remote sensing and computer vision, 4M Analytics helps clients enhance efficiency, avoid delays, and manage costs effectively in construction and infrastructure projects worldwide.

AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.

Justt offers chargeback automation and friendly fraud prevention services designed to minimize merchant revenue loss. The platform is specifically designed for eCommerce businesses, providing hands-free chargeback protection that is particularly suited for Shopify merchants. Justt's solutions leverage artificial intelligence to manage chargebacks effectively, ensuring ongoing optimization of results over time.

Five Sigma LTD. is a software company based in Tel Aviv-Yafo, Israel, that specializes in automating the claims management process for the insurance industry through its cloud-based platform. Founded in 2017, Five Sigma offers a data-driven Claims Management Solution that incorporates artificial intelligence and machine learning capabilities. This platform streamlines claims processing by implementing automated workflows and utilizing data modeling to provide insightful recommendations, enhancing decision-making for insurance adjusters and minimizing errors. The solution is utilized by various entities within the insurance sector, including leading insurance carriers, Insurtech firms, third-party administrators, and self-insured organizations, to modernize their claims operations, reduce claims leakage, ensure compliance, and enhance overall customer experience.

Orna Therapeutics is a biotechnology company focused on developing a new class of fully engineered circular RNA (oRNA) therapeutics aimed at transforming disease treatment. Founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, the company utilizes a proprietary platform that integrates innovative technology for creating circular RNAs designed to enhance protein expression. This platform also incorporates unique delivery solutions to facilitate simplified production, improved formula stability, and superior protein expression, ultimately contributing to advancements in healthcare and therapeutic applications.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, focused on the development of cell and gene-based therapies for treating cancer and viral infections. Founded in 2017 by Vikas Sinha, Mitchell Finer, and David Hallal, ElevateBio operates a portfolio of companies dedicated to creating life-changing medicines. The company collaborates with leading scientists and innovators to build this portfolio and has established a centralized facility that streamlines the transition from research and development to the commercialization of these therapies. This integrated approach enhances efficiency and accelerates the availability of medical products aimed at addressing severe diseases.

AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.

TriNetX, Inc. operates a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a suite of solutions, including TriNetX Live for analyzing patient populations and TriNetX Research for accessing longitudinal clinical data. Its platform integrates electronic medical records and clinical documentation, enabling users to optimize clinical trial design, improve site selection, and accelerate recruitment processes. Additionally, TriNetX offers tools such as Natural Language Processing for extracting clinical facts and specialized resources for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX has expanded its presence internationally with offices in Sydney, London, and Sao Paulo. The platform is designed to be compliant with HIPAA and GDPR regulations, ensuring the secure handling of sensitive health data.

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focused on developing innovative T cell receptor therapies for cancer treatment. The company's leading product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing phase I/II clinical trials for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another candidate, TC-110, targets CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 leverages extensive expertise in T cell biology to create differentiated therapies that stand apart from traditional CAR-T cell treatments.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focused on developing innovative T cell receptor therapies for cancer treatment. The company's leading product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing phase I/II clinical trials for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another candidate, TC-110, targets CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 leverages extensive expertise in T cell biology to create differentiated therapies that stand apart from traditional CAR-T cell treatments.

iPrice Group operates as an online price comparison platform in Southeast Asia, aimed at enhancing the shopping experience by offering a wide selection of products and brands from numerous partners. The company allows consumers to compare prices, discover products, and secure the best deals from thousands of online retailers, catering to various categories including electronics, fashion, home improvements, and baby products. Founded with the goal of increasing transparency, convenience, and trust in the e-commerce market, iPrice has expanded its reach across seven markets, including Indonesia, Vietnam, Singapore, Hong Kong, Thailand, and the Philippines. Supported by investments from the Asia Venture Group, iPrice has developed expertise in technology, online marketing, and business operations, positioning itself as a key player in the region's online shopping landscape.

Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions designed to streamline clinical research for sites, sponsors, contract research organizations (CROs), and patients. Founded in 2006 and headquartered in Horsham, Pennsylvania, with additional offices in Winston-Salem and Cary, North Carolina, Philadelphia, Pennsylvania, and Cambridge, Massachusetts, the company offers a suite of innovative tools including SureSource, an electronic source platform that captures data and documents at the site level, and Lunexis ePRO+, which facilitates patient participation in studies. Additionally, Clinical Ink provides CentrosHealth, a patient engagement platform that includes configurable apps to enhance patient involvement and compliance throughout clinical trials. The company aims to improve clinical trial workflows by integrating electronic data capture and reducing manual processes, ensuring that clients have access to high-quality, validated data.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.

ProterixBio, Inc. develops disease management platforms aimed at improving outcomes for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company focuses on creating proprietary blood-based biomarker tests that provide real-time biological assessments of a patient's disease state. Its ViBE platform, along with Acoustic Membrane MicroParticle (AMMP) assays, utilizes advanced technology to enhance the sensitivity and specificity of traditional diagnostic methods by analyzing proteins in blood, sputum, and other samples. By offering tools that enable healthcare providers to better manage patients, ProterixBio aims to reduce unnecessary hospitalizations and associated healthcare costs. Founded in 2002 and headquartered in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in 2016.

ProterixBio, Inc. develops disease management platforms aimed at improving outcomes for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company focuses on creating proprietary blood-based biomarker tests that provide real-time biological assessments of a patient's disease state. Its ViBE platform, along with Acoustic Membrane MicroParticle (AMMP) assays, utilizes advanced technology to enhance the sensitivity and specificity of traditional diagnostic methods by analyzing proteins in blood, sputum, and other samples. By offering tools that enable healthcare providers to better manage patients, ProterixBio aims to reduce unnecessary hospitalizations and associated healthcare costs. Founded in 2002 and headquartered in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in 2016.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.